首页 News 正文

Publicity of prescription drugs in public places, Baekje Shenzhou Cooperation Company fined 400000 yuan

sxhe
3677 0 0

On January 19th, Red Star Capital Bureau reported that according to the official website of the Shanghai Municipal Administration for Market Regulation, Baekje Shenzhou (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Baekje Shenzhou Biotechnology") has recently been fined 400000 yuan for using advertisements to falsely promote goods or services.
After investigation, it was found that BeiGene Biotech was entrusted by BeiGene (688235. SH; 06160. HK; BGNE. US) to be responsible for the marketing of Pamipali capsules. However, according to public information, there is currently no equity relationship between the two companies.
On January 19th, BeiGene responded to the Red Star Capital Bureau that the company would take it as a warning and strictly comply with relevant laws and regulations in its future work.
On August 18, 2022, BeiGene Biotech held the "Baihuize City Conference" and during the conference, published an advertisement for Pamipali capsules in public areas using a flip flop and promotional flyer as carriers, claiming that "Baihuize (Pamipali) is the only PARP inhibitor approved for the treatment of 3L gBRCAm platinum sensitive and platinum resistant recurrent ovarian cancer; CGCS guidelines recommend Pamipali as the preferred drug for the treatment of recurrent ovarian cancer; the monthly treatment cost for medical insurance patients is only 1929 yuan.".
Data shows that Pamipali capsules are used for the treatment of recurrent advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients who have undergone second-line or above chemotherapy and have germline BRCA (gBRCA) mutations.
But as a prescription drug, it can only be advertised in medical and pharmaceutical professional journals jointly designated by the health administrative department of the State Council and the drug regulatory department of the State Council.
On September 21, 2022, with approval, an investigation was filed into the illegal advertising behavior of BeiGene Biotech.
The Market Supervision Administration of Jing'an District, Shanghai believes that Baekje Shenzhou Biotechnology promotes the above-mentioned prescription drugs in public places through the form of pull-up banners and promotional leaflets. The advertising target audience is not specific and will have an impact on the choices of ordinary patients and consumers without professional medical and pharmaceutical knowledge. It cannot guarantee the scientific, correct, reasonable, and safe use of drugs. Finally, BeiGene Biotech received the Administrative Penalty Hearing Notice on December 27, 2023.
Red Star News reporter Deng Lingyao
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    昨天 11:18
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    3 天前
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    3 天前
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    昨天 17:06
    支持
    反对
    回复
    收藏
sxhe 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0